Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A metastatic variant of a chemically induced lymphoma (ESb) from a
DBA
/2 mouse was found to activate in syngeneic hosts specific anti-tumor cytolytic T lymphocytes (CTL) which recognized on the tumor a distinct tumor-associated antigen. Upon metastasis of a cloned ESb tumor line from an s.c. site to the spleen, the tumor cells which were originally sensitive to lysis by anti-ESb CTL became specifically immunoresistant. The development of immunoresistant variants after tumor-cell transplantation followed a refined kinetic and organ pattern: they were first detected in the spleen, then also in the liver and in the late stage of
tumor progression
they were the predominant tumor type in all involved organs. No immunoresistant tumor variants were generated in immunoincompetent animals such as nude (nu/nu) mice. Immunoresistant variants also developed when immunosensitive ESb clones were inoculated into animals specifically preimmunized against ESb. In fact, these variants were the only type of cells eventually growing out from such animals causing death from metastasis in spite of the specific immune status of the host. The change of tumor antigen expression described here differs from antibody-induced antigenic modulation in that it is genetically transmitted and stable in tissue culture. The immunoresistant tumor variants which did not preexist in the starting, twice-cloned cell population represent a new type of immune escape variant.
...
PMID:High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). 697 2
Moloney murine leukemia virus (M-MuLV) induces promonocytic leukemias, called MML, in pristane-treated adult mice. These tumors invariably express fused gag-myb mRNA as a consequence of virus integration and activation of the c-myb locus. In the present study it was determined that while BALB/c and
DBA
/2N mice are highly susceptible, C57BL/6, C3H/He, STS/A, NFS, NIH/Swiss, SJL/J, and NZB mice are strongly resistant to tumor induction. Although C57BL/6 mice were resistant because they were unable to support early virus replication in hematopoietic tissue, NFS and C3H/He mice supported replication and were shown, using RT-PCR, to have cells in the bone marrow and spleen that expressed the aberrant, leukemia-related gag-myb mRNA. This provided evidence that early stages of leukemia were permitted to develop in these mice, but preneoplastic cells were unable to progress to the acute phase. Experiments in which MML was induced by M-MuLV plus pristane treatment in immunodeficient C3H/He nu/nu and sublethally irradiated C3H/He mice suggested that the immune response may play a role in eliminating preleukemic cells in immunocompetent C3H/He. Tumors from these mice had rearrangements at the c-myb locus and expressed gag-myb RNA. It was concluded that, at least in the case of C3H/He mice, resistance is not due to an inability of virus to activate c-myb or to a lack of other tumor promoting events. Rather, leukemia development appears to be restricted by an immune response, presumably T-cell mediated. Evidence is provided that non-H-2 MHC genes are required for resistance in both C57BL/6 and C3H/He mice and that resistance is dominant. This provides an animal model for the study of
tumor progression
as it relates to the immune response.
...
PMID:Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia. 797 49
BALB/cAn mice are highly susceptible to the induction of plasmacytomas (PCTs) by the i.p. injection of paraffin oils, whereas
DBA
/2 mice are solidly resistant. To search for genes that control the dominant resistant phenotype of
DBA
/2, BALB/c.
DBA
/2 (C.D2) congenic strains were constructed, and the susceptibility and resistance to PCT development were determined. PCT formation takes place over an extended period of 365 days but begins morphologically in focal proliferations of atypical plasma cells (foci) in the reactive oil granuloma that forms on mesenteric surfaces. Cells from some of these foci spread to other locations in oil granuloma tissue, forming new foci. Mice that develop six or more foci appear to be progressing towards eventual overgrowth and replacement of all peritoneal tissues with PCT cells. From Days 100 to 250, between 28 and 56% of PCT-susceptible BALB/cAn mice had 6 or more foci, whereas less than 5% of resistant
DBA
/2, BALB/c x
DBA
/2 F1 (hereafter called CD2F1), C57BL/6, and BALB/cJ mice had 6 or more foci. Four CD2 congenic strains carrying D2 alleles of genes on chromosomes other than chromosome 4 were highly susceptible. Between 0 and 20% of the mice in C.D2-Chr 4 congenic strains C.D2-MIA, C.D2-TF3, C.D2-Fv-1n/n, C.D2-Pnd7, C.D2-Lgm-1A, C.D2-Lgm-1B, C.D2-Lgm-1C, and C.D2-Lgm-1H developed 6 or more foci from 125 to 260 days, indicating resistance. The segments of
DBA
/2 chromosome 4 chromatin in C.D2-Fv-1n/n and C.D2-Pnd7 were discontinuous with those in C.D2-TF3, C.D2-Lgm-1A, C.D2-Lgm-1B, C.D2-Lgm-1C, and C.D2-Lgm-1H, indicating there are at least two genes (Pctr1 and Pctr2) in the distal half of this chromosome that confer resistance. Pctr1 is located between Ifa and D4Rck41, and Pctr2 is between Tnfr-1 and Pkcz. Each locus acting alone distinctly conferred a partial resistant phenotype. Pctr1 and Pctr2 did not appear to prevent the formation of clonal foci but did appear to limit the ability of the plasma cells in foci to acquire greater autonomy; thus, these genes affect
tumor progression
.
...
PMID:Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. 831 88
It is well accepted that inoculation of B7-1-transfected tumor cells into normal mice leads to tumor rejection and subsequent resistance to challenge. However, the effectiveness of B7-2-transfected tumor cells in eliciting protective antitumor immunity is less clear. Here we show that B7-2-transfected P815 tumor cells (B7-2+) are as effective as B7-1-transfected P815 tumor cells (B7-1+) in eliciting protective immunity in normal
DBA
/2 mice. In addition, B7-2+ cells were found to be at least as effective as B7-1+ cells retarding
tumor progression
when admixed with parental P815 tumor cells prior to inoculation into normal mice. Moreover, the B7-2+ cells and the B7-1+ cells were equivalent in their ability to retard tumor growth when administered peritumorally into mice bearing established (approx. 3 mm in diameter) parental P815 tumors. Finally, P815 tumor cells infected with a recombinant replication-defective adenovirus encoding the murine B7-2 gene were effective in retarding the growth of established parental P815 tumors. Thus, B7-1 and B7-2 are comparable in terms of their ability to stimulate the generation of tumor-eradicating immunity in normal mice as well as in mice bearing established parental tumors. Moreover, adenovirus vectors can be used to generate B7-2-expressing tumor cells effective in the immunotherapy of established parental tumors.
...
PMID:Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. 864 Aug 44
The occurrence of different components of the cell growth regulation pathway as expressed in experimental skin carcinogenesis in haired carcinogen-sensitive NMRI, in haired carcinogen resistant
DBA
/2 mice and in hairless SKH/1 mice was studied by morphological and immunohistochemical methods. The results were compared with respect to neoplastic response, number of tumors, tumor behaviour and to the inducing agent (UV irradiation or chemical carcinogen), in order to increase our understanding of specific alterations in neoplastic development caused by extraneous agents and to determine their possible usefulness as indicators of carcinogen exposure. The expression of growth factors (transforming growth factor alpha and epidermal growth factor), growth factor receptors (epidermal growth factor receptor/c-erbB-1 and c-erbB-2/neu), cell signalling component c-myc, the nuclear transcription factor Harvey-Ras and the tumor suppressor gene p53, were studied in carcinogen- and UV-induced tumor formation in mouse. The results showed increased oncogene expression as well as growth factor expression in the skin during tumor development appearing early in neoplastic and premalignant conditions and becoming more distinct during
neoplastic progression
. Efforts to delineate specifically initiated cells prior to the appearance of morphologically detectable alterations including dysplasia, papilloma formation and squamous cell carcinomas, were unsuccessful. Increased staining by antibodies to growth factors and oncogenes were also observed in
DBA
/2 animals resistant to tumor formation. It is concluded that oncogene expression and growth factor protein deposits are associated with carcinogenic effects, partly explaining the mechanism of action of these agents, but the applicability, as such, for the analysis of potential hazardous agents needs further studies.
...
PMID:Oncogenes and growth factors as indicators of carcinogen exposure. 867 68
Considerable evidence supports a role for polyclonal serum natural Ab (NAb) as a mediator of natural resistance against tumors. However, the molecular mechanisms of this NAb activity are not known. Flow cytometry selection of L5178Y-F9 murine T lymphoma cells for high NAb binding provided the variant LYNAb+, which exhibited an inversely corresponding reduction in tumorigenicity. Accompanying the increased NAb binding, LYNAb+ bound more monoclonal 14.8 anti-CD45RA and DNL-1.9 anti-CD45RC and less 13/2 anti-pan CD45, and the binding of MB23G2 anti-CD45RB was eliminated. However, neuraminidase treatment increased NAb binding and detection of pan CD45, CD45RA, and CD45RC but reduced CD45RB expression, suggesting that the epitopes recognized by the former Abs are masked by sialic acid, while the latter includes sialic acid. Growth of the LYNAb+ from a threshold s.c. inoculum in syngeneic
DBA
/2 mice yielded more tumorigenic cells which bound less NAb, anti-CD45RA, and anti-CD45RC; the same very low anti-CD45RB; and more anti-pan CD45. In accord with the mAb binding, the L5178Y-F9 and an in vivo passaged LYNAb+ variant expressed predominantly lower m.w. CD45 isoforms while the LYNAb+ expressed predominantly higher 200-kDa isoforms. The consistent correspondence between CD45RA and CD45RC determinant expression, CD45 isoform expression, tumorigenicity, and NAb binding exhibited by T lymphoma cells selected for high NAb binding in vitro or through
tumor progression
in vivo suggests that asialo high m.w. isoforms of the cell surface-signaling molecule CD45 are differentially expressed during tumor development and furthermore that they participate in NAb-mediated antitumor mechanisms.
...
PMID:Differential CD45 isoform expression accompanies reduced natural antibody binding in L5178Y-F9 tumor progression. 920 Apr 72
Overexpression of cyclooxygenase-2 (COX-2) is seen in a high percentage of human colon tumors, lung adenocarcinomas and other cancers. Inhibition of this enzyme represses human colon tumorigenesis and decreases lung tumor multiplicity in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-exposed A/J mice. The purpose of this investigation was to characterize the expression of cyclooxygenase-2 (COX-2) during
tumor progression
in the A/J mouse lung and to compare the results with expression in other cancer-susceptible and several cancer-resistant mouse strains. Analysis of normal A/J mouse lung showed that type II alveolar epithelial cells express high levels of COX-2 protein and mRNA, indicating that COX-2 is present constitutively in this tumor progenitor cell prior to any carcinogen exposure. Examination of lung-cancer-resistant (C3H/HeJ, C57BL/6J,
DBA
/2J) and other lung-cancer-susceptible (A/WySnJ, SWR/J) strains showed similar levels of COX-2 mRNA expression in the three susceptible strains and lower levels of expression in two of the resistant strains, indicating a possible correlation between COX-2 expression in type II cells and lung cancer susceptibility. COX-2 protein expression was observed in A/J lung tumors at all stages of development. Variation and occasional absence of protein expression were also observed in A/J lung tumors, particularly in adenomas and adenocarcinomas, suggesting that COX-2 is not obligatory for maintenance of the malignant phenotype. In support of this conclusion, treatment of xenografted cell lines derived from malignant murine pulmonary tumors with COX-2 inhibitors produced only a slight repression of growth. However, the frequent expression of COX-2 in early lesions in the A/J mouse lung combined with the known reduction in tumor number in animals treated with COX-2 inhibitors prior to carcinogen exposure indicate that COX-2 could be a promising target for lung cancer chemoprevention. In addition, high levels of COX-2 expression in the normal tumor-progenitor cells of lung-cancer-sensitive mice indicate that COX-2 may play a role in lung cancer susceptibility.
...
PMID:Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. 1087 16
Subcutaneous in vivo injections of cells of the mastocytoma line P815 in syngenic
DBA
/2 mice induce locally fast growing solid tumors. These have been used extensively as a cancer model to analyze and manipulate the relationship between tumor cells and host's immune defenses. We report that progression of P815 tumors in vivo was accompanied by a burst (Days 5-7) of local inflammatory cells recruitment and angiogenesis observed histologically, corroborated in vivo by MRI with gadolinium, overtranscription of macrophage activation marker genes, secretion of TNF-alpha by regional lymph node cells and concomitant systemic inflammation. No substantial overtranscriptions of either VEGF or IL-10 or TGF-beta genes were observed. Induction of COX-2 gene was a late event. To establish a possible relationship between the tumor-induced local, regional and systemic increase of pro-inflammatory mediators and progression of tumors in vivo, we carried out experiments deliberately modulating the inflammatory status of the recipient animals. Pretreatment of recipient animals by i.p. injection of thioglycolate accelerated P815 tumor growth. At the opposite, treatment of mice with either a COX-1 + COX-2 inhibitor (aspirin, 1 mg/day/mouse) or a specific COX-2 inhibitor (celecoxib, 0.13 mg/day/mouse) for 2 weeks after injection of tumor cells, significantly reduced the size and growth rate of tumors compared to control mice. Experiments carried out in vitro indicated that peritoneal macrophages from untreated animals were strongly activated by live P815 cells and by P815 membrane preparations. The tumor-induced inflammatory reaction could establish a local micro environment favoring
tumor progression
. The P815 tumor model might be helpful to recognize important factors controlling host/tumor relationship.
...
PMID:Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences. 1212 7
Certain inbred strains of mice, including
DBA
/2J, develop adrenocortical tumors in response to gonadectomy. Spindle-shaped cells with limited steroidogenic capacity, termed A cells, appear in the subcapsular region of the adrenal gland, followed by sex steroid-producing cells known as B cells. These changes result from unopposed gonadotropin production by the pituitary, but the adrenocortical factors involved in tumorigenesis have not been characterized. GATA-4, a transcription factor normally expressed in fetal, but not adult, adrenocortical cells, was found in neoplastic cells that proliferate in the adrenal cortex of gonadectomized
DBA
/2J mice. GATA-4 mRNA was detected in the adrenal glands of female mice 0.5 months after ovariectomy and reached a maximum by 4 months. Castrated male mice developed adrenocortical tumors more slowly than gonadectomized females, and the onset of GATA-4 expression in the adrenal was delayed. In situ hybridization and immunohistochemistry revealed GATA-4 mRNA and protein in A and B cells, but not in normal adrenocortical cells. mRNA encoding another factor associated with adrenocortical tumorigenesis, LH receptor (LHR), was detected in A and B cells. In addition, transcripts for P450 17 alpha-hydroxylase/C17-C20 lyase, an enzyme essential for the production of sex steroids, and inhibin-alpha were found in B cells. Unilateral ovarian regeneration, a phenomenon known to occur in gonadectomized mice, was observed in a subset of
DBA
/2J mice undergoing complete ovariectomy. In these animals, adrenocortical
tumor progression
was arrested; A cells and GATA-4 expression were evident, but there was no expression of LHR or P450 17 alpha-hydroxylase/C17-C20 lyase. Strain susceptibility to adrenocortical tumorigenesis (
DBA
/2J >> FVB/N) correlated with the expression of GATA-4 and LHR, implicating these factors in the process of adrenocortical neoplasia in response to continuous gonadotropin stimulation.
...
PMID:Mouse strain susceptibility to gonadectomy-induced adrenocortical tumor formation correlates with the expression of GATA-4 and luteinizing hormone receptor. 1293 87
A lectin is "a protein or glycoprotein of non-immune origin, not an enzyme, that binds to carbohydrates and agglutinates cells" (1). Lectins are naturally occurring substances, most commonly derived from plant or sometimes invertebrate sources, that can be exploited in the laboratory to detect and reveal carbohydrate structures in or on the surface of cells in very much the same way that antibodies can be used to reveal specific antigens. Lectins can detect very subtle alterations in cellular glycosylation. This is of interest in metastasis research as there is increasing evidence that marked glycosylation changes can attend both transformation to malignancy and
tumor progression
. Lectins are named after the source from which they are derived-sometimes the Latin binomial (e.g., Bandeirea simplicifolia lectin or Dolichos biflorus lectin), sometimes the common name (e.g., peanut lectin or wheatgerm lectin), or some-times by a slightly obscure historical term (e.g., Concanavalin A [Con A] for the lectin from Canavalia ensiformis, the jack bean). The term lectin is used fairly interchangeably with the older term "agglutinin," as in peanut agglutinin or Helix pomatia agglutinin. Lectins are often referred to by an abbreviation for their names, for example, PNA (peanut agglutinin) or
DBA
(Dolichos biflorus agglutinin); obscurely, PHA, which actually stands for phytohaemagglutinin is, for historical reasons, the abbreviation usually employed for the lectin derived from Phaseolus vulgaris. Many sources yield more than one lectin, termed isolectins, which may have quite different carbohydrate binding specificities (e.g., the gorse Ulex europaeus yields two major isolectins, Ulex europaeus agglutinin I [UEA-I], which has a strong binding preference for fucose, and Ulex europaeus agglutinin II [UEA-II], which has a strong binding preference for N-acetylglucosamine).
...
PMID:Lectin histochemistry to detect altered glycosylation in cells and tissues. 2134 Aug 90
<< Previous
1
2
3
Next >>